Led · Series B · Oct 2025

Kailera Therapeutics is advancing a differentiated portfolio of obesity treatments spanning both injectable and oral modalities. Its lead candidate, KAI-9531, is an injectable dual GLP-1/GIP receptor agonist that has shown potentially best-in-category weight-loss efficacy and is expected to enter global Phase 3 trials by the end of 2025. The company is also preparing KAI-7535, an oral small-molecule GLP-1 receptor agonist that achieved competitive weight loss in a Phase 2 study in China, for worldwide clinical development. Earlier-stage assets include KAI-4729, an injectable GLP-1/GIP/glucagon tri-agonist, and an oral tablet formulation of KAI-9531. Kailera additionally holds rights to new formulations and first-refusal options on selected metabolic assets from Hengrui. Headquartered in Waltham, Massachusetts, and San Diego, California, the company’s recent $600 million Series B financing provides the capital needed to progress its late-stage and early-stage programs toward commercialization.

Participated · Series B · Jul 2024

Cardurion Pharmaceuticals is a clinical-stage biotech focused on discovering and developing novel therapeutics for cardiovascular diseases. Its two lead programs are a first-in-class phosphodiesterase-9 (PDE9) inhibitor, CRD-750, and the first clinical-stage CaMKII inhibitor, CRD-4730. CRD-750 is being evaluated in two Phase 2 trials enrolling 640 patients across HFrEF and HFpEF populations, and CRD-4730 has an ongoing Phase 2 trial for catecholaminergic polymorphic ventricular tachycardia (CPVT). The company plans to expand cardiovascular indications for its portfolio, progress internal discovery programs, and acquire additional therapeutic assets. Proceeds from the recent financing will also be used to scale the team and build cardiovascular drug-development capabilities. Cardurion is headquartered in Burlington, Massachusetts, with discovery and research facilities in Shonan, Japan. Cardurion Pharmaceuticals is a clinical-stage biotechnology company developing next-generation therapeutics for heart failure and other cardiovascular diseases by targeting cardiovascular signaling pathways. The company’s pipeline includes a PDE9 inhibitor and a CaMKII inhibitor program. Cardurion plans to advance its first-in-class PDE9 inhibitor into a major Phase 2 trial in heart failure and to initiate first-in-human studies for its CaMKII inhibitor across several cardiovascular indications. The recently announced financing will support thoughtful advancement of the pipeline, scaling of the team, and creation of an industry-leading platform. Cardurion was founded by physician-scientist Michael E. Mendelsohn and has facilities in Boston, Massachusetts and Shonan, Japan. Cardurion Pharmaceuticals is a biotechnology company developing novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Its lead clinical program is CRD-733, a novel phosphodiesterase-9 (PDE9) inhibitor in development for both forms of heart failure. The company also has two discovery programs focused on unique molecular targets for other cardiovascular diseases, including rare and more common arrhythmia disorders. Cardurion was founded by physician-scientist Michael E. Mendelsohn and pursues unique drug discovery and development programs in cardiovascular medicine. The company operates facilities in Boston, Massachusetts and Shonan, Japan. It has existing investor Takeda Pharmaceuticals and has consummated a private investment from Polaris Partners; the securities issued are unregistered and subject to applicable exemptions under U.S. securities laws.

Led · Series C · Nov 2021

Linc'well is a Japan-based healthcare software provider. The company announced an 8 billion yen Series C funding round. Bain Capital Private Equity led the financing, which was reported as roughly $69.7 million. The raise was disclosed in a company statement. The article did not provide additional details on product specifics, operating metrics, use of proceeds, or other investors.

Led · Series A · Apr 2021

pulseData builds a suite of artificial intelligence solutions that predict the progression of chronic kidney disease and cardiorenal comorbidities. Its customers include Medicare Advantage plans, commercial health plans, self-insured employers, risk-bearing health systems, Accountable Care Organizations, and providers participating in value-based care. Led by co-founders Teddy Cha (CEO) and Hai Po Sun (CTO), the New York City-based company focuses on applying predictive algorithms to chronic disease management. In April 2021 pulseData raised $16.5m in a Series A funding round led by Bain Capital Private Equity and Two Bear Capital, with participation from Alumni Ventures Group and existing investors. The company said it will use the funds to expand operations and broaden its business reach.

Led · Equity · Mar 2021

Newlink Group is a Beijing-based company that leverages AI and big data technologies to digitise energy transportation. The company's core focus is on digitising energy transportation using AI and big-data approaches. The firm announced it had secured 900 million yuan (approximately $133 million) in its latest funding round. That funding was raised via its subsidiaries, according to the company. The announcement was made last Saturday. The article does not disclose investors, financing instruments, operating metrics, or any use of proceeds or future plans. NewLink Group is a Chinese provider of technology solutions and services to the energy sector, described in the article as focusing on digital energy solutions. The company offers technology solutions and services tailored to energy customers. The report highlights the firm's core area as digital energy but does not detail specific products or customers. On Wednesday it announced a ¥2 billion (US$308 million) Series E financing. The financing was led by private equity firm China Merchants Capital, and the article does not disclose operating metrics, use of proceeds, or additional strategic details. Newlink Group is an online platform that helps drivers connect gas stations and charging piles across China. The company operates across China, facilitating connections between drivers and fuel and electric charging infrastructure. On Monday the company announced it has received a strategic investment of $200 million. The financing was led by Bain Capital Private Equity. The article characterizes the transaction as a strategic investment but does not specify the exact instrument or list additional investors. The article does not provide operating metrics, valuation, founding year, or details on future plans. Newlink Group is a Chinese energy services platform. The company raised 900 million yuan (about $129 million) in a Series D round of financing. The round was led by CICC Capital, the private equity arm of China International Capital Corporation. The article reports the amount and lead investor but does not detail other participating investors or deal terms. No operating metrics, past-round details, or founding-year information are provided in the article.